A gliclazide complex based on palladium towards Alzheimer's disease: promising protective activity against Aβ-induced toxicity in <i>C. elegans</i>

García-García, Amalia; Garcia, Lorenzo Rivas; Navarro-Hortal, María D.; Romero-Márquez, Jose M.; Fernandez‐Bolanos, J.; Choquesillo-Lazarte, Duane; Salinas-Castillo, Alfonso; López, Óscar; Quiles, José L.; Rodríguez-Diéguez, Antonio

doi:10.1039/d1cc04404d

Cited by 11 publications

(1 citation statement)

References 24 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, our research group published a complex based on palladium and the antidiabetic drug gliclazide (glz), [Pd(glz) 2 ]. 67 Originally, we selected glz as the organic moiety in the preparation of AD's metallodrugs since several factors associate Diabetes mellitus with AD: (i) it is a risk factor for Alzheimer's disease, (ii) it has a similar molecular mechanism of action, and (iii) it is associated with protein misfolding. 77,78 Thus, the potential of [Pd(glz) 2 ] against AD was explored, obtaining the preferential inhibition of BuChE against AChE (91 vs. 58% inhibition), with an IC 50 value of 27 μM for BuChE, as it is capable of interacting with both the free enzyme and the enzyme–substrate complex.…”

Section: Discrete Coordination Compounds In Ad Treatmentmentioning

confidence: 99%

Therapy and diagnosis of Alzheimer's disease: from discrete metal complexes to metal–organic frameworks

García-García

Rodríguez-Diéguez

2023

J. Mater. Chem. B

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discrete Coordination Compounds In Ad Treatmentmentioning

confidence: 99%

Therapy and diagnosis of Alzheimer's disease: from discrete metal complexes to metal–organic frameworks

García-García

Rodríguez-Diéguez

2023

J. Mater. Chem. B

Self Cite

View full text Add to dashboard Cite

show abstract

The Design of Metal Complexes to Target the Amyloid‐β Peptide in Alzheimer's Disease

Webb

2023

Encyclopedia of Inorganic and Bioinorganic Chemistry

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a devastating neurological disorder where a pathological hallmark is the occurrence of amyloid‐β (Aβ) peptide deposits, also known as Aβ plaques. The Aβ peptide is known to self‐associate and aggregate in solution, a phenomenon that is accelerated in the presence of metal ions, in particular Fe, Cu, and Zn. Furthermore, these micronutrient metals are found in elevated concentration within Aβ plaques, relative to nearby healthy tissues. Therapeutic approaches have sought to exploit this metalloprotein nature of Aβ by designing metal complexes that can target either the soluble peptide or its pathological aggregate species. Overall, complexes of 27 different metals have been designed to target the Aβ that can detect its presence in biological samples, modulate its aggregation, and/or prevent its neurotoxic activity. This article summarizes these compounds, and the advances made for complexes of each metal.

show abstract

Transition Metal Complexes as Therapeutics: A New Frontier in Combatting Neurodegenerative Disorders through Protein Aggregation Modulation

Navale,

Ahmed,

Lim

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Neurodegenerative disorders (NDDs) are a class of debilitating diseases that progressively impair the protein structure and result in neurological dysfunction in the nervous system. Among these disorders, Alzheimer's disease (AD), prion diseases such as Creutzfeldt‐Jakob disease (CJD), and Parkinson's disease (PD) are caused by protein misfolding and aggregation at the cellular level. In recent years, transition metal complexes have gained significant attention for their potential applications in diagnosing, imaging, and curing these NDDs. These complexes have intriguing possibilities as therapeutics due to their diverse ligand systems and chemical properties and can interact with biological systems with minimal detrimental effects. This review focuses on the recent progress in transition metal therapeutics as a new era of hope in the battle against AD, CJD, and PD by modulating protein aggregation in vitro and in vivo. It may shed revolutionary insights into unlocking new opportunities for researchers to develop metal‐based drugs to combat NDDs.

show abstract

A gliclazide complex based on palladium towards Alzheimer's disease: promising protective activity against Aβ-induced toxicity in C. elegans

Abstract: A new palladium coordination compound based on gliclazide with the chemical formula [Pd(glz)2] (where glz = gliclazide) has been synthesized and characterised. The structural characterization reveals that this material consists...

Cited by 11 publications

References 24 publications

Therapy and diagnosis of Alzheimer's disease: from discrete metal complexes to metal–organic frameworks

Therapy and diagnosis of Alzheimer's disease: from discrete metal complexes to metal–organic frameworks

The Design of Metal Complexes to Target the Amyloid‐β Peptide in Alzheimer's Disease

Transition Metal Complexes as Therapeutics: A New Frontier in Combatting Neurodegenerative Disorders through Protein Aggregation Modulation

Contact Info

Product

Resources

About